Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
30. März 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 30, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application...